Cargando…

Maximizing the Potency of siRNA Lipid Nanoparticles for Hepatic Gene Silencing In Vivo**

Detalles Bibliográficos
Autores principales:	Jayaraman, Muthusamy, Ansell, Steven M, Mui, Barbara L, Tam, Ying K, Chen, Jianxin, Du, Xinyao, Butler, David, Eltepu, Laxman, Matsuda, Shigeo, Narayanannair, Jayaprakash K, Rajeev, Kallanthottathil G, Hafez, Ismail M, Akinc, Akin, Maier, Martin A, Tracy, Mark A, Cullis, Pieter R, Madden, Thomas D, Manoharan, Muthiah, Hope, Michael J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	WILEY-VCH Verlag 2012
Materias:	Communications
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3470698/ https://www.ncbi.nlm.nih.gov/pubmed/22782619 http://dx.doi.org/10.1002/anie.201203263

Ejemplares similares

Influence of Polyethylene Glycol Lipid Desorption Rates on Pharmacokinetics and Pharmacodynamics of siRNA Lipid Nanoparticles
por: Mui, Barbara L, et al.
Publicado: (2013)

Modulation of thermal stability can enhance the potency of siRNA
por: Addepalli, Haripriya, et al.
Publicado: (2010)

RNA duplexes with abasic substitutions are potent and allele-selective inhibitors of huntingtin and ataxin-3 expression
por: Liu, Jing, et al.
Publicado: (2013)

A Glu-urea-Lys Ligand-conjugated Lipid Nanoparticle/siRNA System Inhibits Androgen Receptor Expression In Vivo
por: Lee, Justin B, et al.
Publicado: (2016)

Acyclic (S)-glycol nucleic acid (S-GNA) modification of siRNAs improves the safety of RNAi therapeutics while maintaining potency
por: Egli, Martin, et al.
Publicado: (2023)

Impact of enhanced metabolic stability on pharmacokinetics and pharmacodynamics of GalNAc–siRNA conjugates
por: Nair, Jayaprakash K., et al.
Publicado: (2017)

Influence of Cationic Lipid Composition on Gene Silencing Properties of Lipid Nanoparticle Formulations of siRNA in Antigen-Presenting Cells
por: Basha, Genc, et al.
Publicado: (2011)

Advanced siRNA Designs Further Improve In Vivo Performance of GalNAc-siRNA Conjugates
por: Foster, Donald J., et al.
Publicado: (2018)

Identification of siRNA delivery enhancers by a chemical library screen
por: Gilleron, Jerome, et al.
Publicado: (2015)

Systemic RNAi-mediated Gene Silencing in Nonhuman Primate and Rodent Myeloid Cells
por: Novobrantseva, Tatiana I, et al.
Publicado: (2012)

Allele-Selective Inhibition of Mutant Atrophin-1 Expression by Duplex and Single-Stranded RNAs
por: Hu, Jiaxin, et al.
Publicado: (2014)

Safety evaluation of 2′-deoxy-2′-fluoro nucleotides in GalNAc-siRNA conjugates
por: Janas, Maja M, et al.
Publicado: (2019)

Investigating the pharmacodynamic durability of GalNAc–siRNA conjugates
por: Brown, Christopher R, et al.
Publicado: (2020)

Shielding of Lipid Nanoparticles for siRNA Delivery: Impact on Physicochemical Properties, Cytokine Induction, and Efficacy
por: Kumar, Varun, et al.
Publicado: (2014)

Structural basis for the synergy of 4′- and 2′-modifications on siRNA nuclease resistance, thermal stability and RNAi activity
por: Harp, Joel M, et al.
Publicado: (2018)

Lipid Nanoparticle Delivery of siRNA to Silence Neuronal Gene Expression in the Brain
por: Rungta, Ravi L, et al.
Publicado: (2013)

Evaluation of GalNAc-siRNA Conjugate Activity in Pre-clinical Animal Models with Reduced Asialoglycoprotein Receptor Expression
por: Willoughby, Jennifer L.S., et al.
Publicado: (2018)

Stabilizing contributions of sulfur-modified nucleotides: crystal structure of a DNA duplex with 2′-O-[2-(methoxy)ethyl]-2-thiothymidines
por: Diop-Frimpong, Benjamin, et al.
Publicado: (2005)

Selection of GalNAc-conjugated siRNAs with limited off-target-driven rat hepatotoxicity
por: Janas, Maja M., et al.
Publicado: (2018)

Selection of hyperfunctional siRNAs with improved potency and specificity
por: Wang, Xiaowei, et al.
Publicado: (2009)

Molecularly Self-Assembled Nucleic Acid Nanoparticles for Targeted In Vivo siRNA Delivery
por: Lee, Hyukjin, et al.
Publicado: (2012)

Development of Lipidoid Nanoparticles for siRNA Delivery to Neural Cells
por: Khare, Purva, et al.
Publicado: (2021)

Competition for RISC binding predicts in vitro potency of siRNA
por: Koller, Erich, et al.
Publicado: (2006)

High potency silencing by single-stranded boranophosphate siRNA
por: Hall, Allison H. S., et al.
Publicado: (2006)

Lipid Nanoparticles Containing siRNA Synthesized by Microfluidic Mixing Exhibit an Electron-Dense Nanostructured Core
por: Leung, Alex K. K., et al.
Publicado: (2012)

Correction to “Lipid Nanoparticles Containing siRNA Synthesized by Microfluidic Mixing Exhibit an Electron-Dense Nanostructured Core”
por: Leung, Alex K. K., et al.
Publicado: (2012)

Synthesis, chirality-dependent conformational and biological properties of siRNAs containing 5′-(R)- and 5′-(S)-C-methyl-guanosine
por: Mikami, Atsushi, et al.
Publicado: (2020)

Advances in Lipid Nanoparticles for siRNA Delivery
por: Tam, Yuen Yi C., et al.
Publicado: (2013)

Predicting siRNA potency with random forests and support vector machines
por: Wang, Liangjiang, et al.
Publicado: (2010)

Specificity, duplex degradation and subcellular localization of antagomirs
por: Krützfeldt, Jan, et al.
Publicado: (2007)

siRNA potency enhancement via chemical modifications of nucleotide bases at the 5′-end of the siRNA guide strand
por: Shinohara, Fumikazu, et al.
Publicado: (2021)

Therapeutic Potency of Nanoformulations of siRNAs and shRNAs in Animal Models of Cancers
por: Karim, Md. Emranul, et al.
Publicado: (2018)

Harnessing a Physiologic Mechanism for siRNA Delivery With Mimetic Lipoprotein Particles
por: Nakayama, Tomoko, et al.
Publicado: (2012)

siRNA Off-Target Effects Can Be Reduced at Concentrations That Match Their Individual Potency
por: Caffrey, Daniel R., et al.
Publicado: (2011)

Overcoming GNA/RNA base-pairing limitations using isonucleotides improves the pharmacodynamic activity of ESC+ GalNAc-siRNAs
por: Schlegel, Mark K, et al.
Publicado: (2021)

Centyrin ligands for extrahepatic delivery of siRNA
por: Klein, Donna, et al.
Publicado: (2021)

Cross-Species Translation of Biophase Half-Life and Potency of GalNAc-Conjugated siRNAs
por: Boianelli, Alessandro, et al.
Publicado: (2022)

Chirality matters: stereo-defined phosphorothioate linkages at the termini of small interfering RNAs improve pharmacology in vivo
por: Jahns, Hartmut, et al.
Publicado: (2021)

siRNA carrying an (E)-vinylphosphonate moiety at the 5΄ end of the guide strand augments gene silencing by enhanced binding to human Argonaute-2
por: Elkayam, Elad, et al.
Publicado: (2017)

siRNA carrying an (E)-vinylphosphonate moiety at the 5΄ end of the guide strand augments gene silencing by enhanced binding to human Argonaute-2
por: Elkayam, Elad, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_k90ih4d4asukrmpv113ht4rg59